Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy. [...]


CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021
Dr James L Januzzi

Heart Failure Care Beyond City Limits: Insights from a Cardiologist

Implementation of STRONG-HF protocol in heart failure management: an Australian perspective

Unleashing the Power of STRONG-HF: Enabling Transformation in Heart Failure Management Across China

When every minute counts: A deep dive into IJN Malaysia’s quest for rapid triage for chest pain patients in the ED

Screening & Diagnosis of Heart Failure in Pre-Diabetic and Diabetic Patients

Elevating CVD management in APAC to its Zenith- with Cardiac biomarkers 

Quantum leap in reducing rehospitalization in HF by 70-80% – How and where?

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

STRONG-HF: Rapid Uptitration of Guideline Directed Medical Therapy for Heart Failure

Guidelines Interpretation – Guidelines for the management of chronic heart failure in dialysis patients in China

Heart failure management in Australia and the role of NT-proBNP in monitoring and treatment

Download APAC STRONG-HF Master Pack: First-hand Insights from Prof Mebazaa on Heart Failure Treatment Monitoring

Perioperative myocardial injury (PMI) management: Challenges and feasibility of active screening in non-cardiac surgeries

Heart Failure Management in India – Overcoming Present Challenges

STRONG-HF study highlighting benefits of treatment optimisation

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

NT-proBNP and ECHO in heart failure – do they always go hand in hand?

High Sensitivity Cardiac Troponins and ACS – the Malaysian Experience

Rational use of troponin and optimal management of cardiovascular diseases

The evidence for 0/1-hour algorithm for Asia? DROP-Asian ACS Study

Process Optimization for Emergency hs-TnT Detection

Clinical Application Value of NT-proBNP in Chronic Kidney Diseases Patients with Cardiovascular Diseases

Uncovering the Cardio-renal Risks of Chinese T2DM patients: Back to the Future with CUHK!

High Sensitivity Troponin vs Conventional Troponin: An Expert View

The rationale for the use of hs-Tn in the optimal management of ACS

Management of Diabetes in Japan – Can Patients Play a More Significant Role?

T2DM Patient Support Program in Hong Kong and the Value of NT-proBNP

Role of Diagnostics: NT-proBNP in management of Heart Failure

Taking Diabetes to Heart: Value of Cardiovascular Biomarkers for your Diabetic Patients

ESC 2021 Heart Failure Guidelines: What’s new?

Heart Failure in Hong Kong- Present Challenges and Future Strategies

Tips for implementing ESC high sensitivity cardiac troponin (hs-cTn) rapid algorithms for triage of AMI patients

Rapid Algorithms for Faster Triage of ED Patients with Suspected AMI – What Are We Waiting For?

Comparing the ESC high sensitivity cardiac troponin (hs-cTn) rapid algorithms for triage of AMI patients

STROKESTOP II Study: Precision risk screening for atrial fibrillation in elderly

Atrial Fibrillation in Elderly: Screening tools and role of NT-proBNP

Advantages of early NT-proBNP testing in patients suspected with heart failure

NT-proBNP: Increasing Clinical Confidence in Heart Failure Management

What is the Peptide for Life initiative?

Digital Prediction Platforms: A catalyst towards personalized CVD prognosis

Heart Failure in Asia – Present Challenges and Future Strategies

Perioperative Myocardial Infarction in Non-Cardiac Surgery – Why Measuring Troponin is Important?

Heart Failure Prevention in T2DM – Essence of JCS/JDS joint consensus

Clinical Cases: Differentiating acute from chronic cardiac conditions

Clinical Cases: Diagnostic relevance of elevated hs-cTnT

Clinical Cases from Korea: Serial NT-proBNP measurement and Heart Failure prognosis

Clinical Cases from Korea: NT-proBNP for Differential diagnosis of patients with dyspnoea

Clinical Cases from Korea: Value of NT-proBNP in Cardiomyopathy

Clinical Cases from Korea: High NT-proBNP levels useful in differential diagnosis of HF

CVD Management in T2DM – JCS and JDS Joint Consensus

ESC Recommendation: High sensitivity troponin assay vs conventional assay

ESC Recommendation: Rapid algorithms using hs troponin in ED

Dr David Sim’s Clinical Cases: NT-proBNP in Heart Failure Patients

CANVAS study: NT-proBNP and CVD risk reduction

Clinical Cases: Elevations of hs-TnT in Non-cardiac Conditions

Clinical Cases: hs-TnT in Patients with End Stage Renal Failure

Clinical Cases: Serial Monitoring Differentiates Acute and Chronic hs-TnT Elevation

Dr Lee’s Clinical Cases: hs-TnT Chronic Elevation non-AMI cases

Dr Lee’s Clinical Cases: hs-TnT Early “Rule-In” for AMI

FAQ: NT-proBNP Interpretation in Multiple Scenarios

FAQ: NT-proBNP vs Cardiac Medications

FAQ: Role of NT-proBNP in Heart Failure Management

At the forefront of Acute Coronary Syndrome management in ED

What should we take note of when using hs-TnT for CKD patient?

Clinical Relevance of hs-Tn age specific cut-offs?

Clinical Relevance of hs-TnT gender specific cut-offs

Recommended Steps to Implement 0h/1h Algorithm in Asia

Benefits of 0h/1h Algorithm in a Thai Institution

Benefits of 0h/1h Algorithm to Patients in Asia

How will NT-proBNP testing evolve in the future?

Is NT-proBNP validated for different population groups?

Reference ranges for NT-proBNP & hs-TnT in Asian populations

How to Implement ESC Rapid Algorithm Successfully?

The Changes in Rapid Algorithms for Acute Coronary Syndrome

Factors affecting high-sensitivity cardiac troponin levels

DAPA-HF and EMPEROR-Reduced Study Highlights

The role of biomarkers in HF

Digital health in HF management

Benefits of the 0h/1h algorithm in a Japanese institution

Serial testing of hs cTn rules out low risk of AMI

Patient Case Studies Using 0h/1h Algorithm

Latest IFCC Recommendations for Natriuretic Peptides in Heart Failure – Analytics and Clinical Considerations

Natriuretic Peptide Measurement during ARNi Treatment

Impact of ARNi Therapy on Natriuretic Peptide Use

Summary of APSC High Sensitivity Troponin T Consensus

NT-proBNP in Hospital & Ambulatory Settings: Evidence to Clinical Practice

How to Use NT-proBNP for Prognosis and Monitoring?

What Should Hospitals Consider when Implementing Rapid Algorithm?

Early triage of patients with acute chest pain with hs-TnT 0h/1h Algorithm

APSC hs-TnT Consensus & Future Use of Biomarker in T2DM & COVID-19

TRAPID-AMI Sub-Study: Single Low Concentration of hs-TnT to Rule Out AMI

Benefits of hs-Tn 0h/1h Algorithm in ED & Hospital

TRAPID-AMI Study: hs-TnT for Rapid Rule In/ Out of AMI

Benefits of hs-Tn 0h/1h Algorithm to Chest Pain Patients

Management of Cardiovascular Risks of COVID-19 Patients

How NT-proBNP Made a Difference: Dr Januzzi’s Patient Story

Impact of hs-Tn on Further Cardiac Testing in Suspected AMI Patients

COVID-19 and the Heart, Experience from Front Line

Switching from Conventional to hs-Troponin

How hs-TnT Made a Difference – Dr Twerenbold’s Story

How NT-proBNP Made a Difference: Dr Richards’ Patient Story

Natriuretic Peptides in the Latest ESC & AHA HF Guidelines

Role of Natriuretic Peptides in Patients with Dypsnea

Novel Biomarker-based Risk Score in AF: ABC Risk Score

Interpreting Elevated Troponin Results

hs-TnT Rapid Diagnosis of AMI- ESC 0h/3h Algorithm

hs-TnT Rapid Diagnosis of AMI- ESC 0h/1h Algorithm

2800+ Healthcare Professionals have cardiac insights delivered to their inbox
Sign up to receive the latest updates via your email
Keep me informed